Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis

  • M. N
  • K. N
  • Y. M
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


We report here the results of therapeutic trials in 200 patients with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) conducted in our department between 1986 and 1993. Motor disability grades were improved by more than one grade in 69.5% (91/131) of patients by oral administration of prednisolone, 50% (3/6) by eperisone hydrochloride only, 43.8% (7/16) by blood purification (lymphocytapheresis and plasmapheresis), 40.0% (2/5) by intrathecal injection of hydrocortisone, 30.0% (3/10) by intravenous injection of high-dose methylprednisolone, 23.3% (10/43) by interferon-alpha (intramuscular injection and inhalation), 22.2% (2/9) by azathioprine, 20.0% (4/20) by high-dose vitamin C, 16.0% (4/25) by erythromycin, 12.5% (3/24) by salazosulfapyridine, 11.8% (2/17) by mizoribine, 7.1% (1/14) by fosfomycin, and 6.3% (1/16) by thyrotropin releasing hormone. No critical side effects of these therapies were seen with the exceptions of one patient with adult respiratory distress syndrome due to cytomegalovirus infection and one patient with drug-induced hepatitis/hepatic failure. Selection of these treatments for patients with HAM/TSP must be considered on the basis of age, sex, disease severity and complications to reduce adverse events and to improve quality of life. Although the results were a synopsis of different treatments given to 200 patients with HAM/TSP as an open trial, we consider this the first report of a large-scale therapeutic trial in patients with HAM/TSP. The results of this study indicate that immunomodulatory therapies have some beneficial effects in HAM/TSP, and the functions of these agents are related to the pathophysiology of this disease.

Author-supplied keywords

  • *eperisone/ae [Adverse Drug Reaction]
  • *eperisone/ct [Clinical Trial]
  • *eperisone/dt [Drug Therapy]
  • *hydrocortisone/ae [Adverse Drug Reaction]
  • *hydrocortisone/ct [Clinical Trial]
  • *hydrocortisone/dt [Drug Therapy]
  • *prednisolone/ae [Adverse Drug Reaction]
  • *prednisolone/ct [Clinical Trial]
  • *prednisolone/dt [Drug Therapy]
  • *spastic paraplegia/dt [Drug Therapy]
  • *spastic paraplegia/th [Therapy]
  • *spinal cord disease/dt [Drug Therapy]
  • *spinal cord disease/th [Therapy]
  • abdominal pain/si [Side Effect]
  • adolescent
  • adult
  • adult respiratory distress syndrome/si [Side Effec
  • aged
  • alpha interferon/ae [Adverse Drug Reaction]
  • alpha interferon/ct [Clinical Trial]
  • alpha interferon/dt [Drug Therapy]
  • anorexia/si [Side Effect]
  • article
  • ascorbic acid/ae [Adverse Drug Reaction]
  • ascorbic acid/ct [Clinical Trial]
  • ascorbic acid/do [Drug Dose]
  • ascorbic acid/dt [Drug Therapy]
  • azathioprine/ct [Clinical Trial]
  • azathioprine/dt [Drug Therapy]
  • bronchitis/si [Side Effect]
  • child
  • clinical trial
  • diarrhea/si [Side Effect]
  • erythromycin/ae [Adverse Drug Reaction]
  • erythromycin/ct [Clinical Trial]
  • erythromycin/dt [Drug Therapy]
  • fatigue/si [Side Effect]
  • female
  • fosfomycin/ae [Adverse Drug Reaction]
  • fosfomycin/ct [Clinical Trial]
  • fosfomycin/dt [Drug Therapy]
  • fracture/si [Side Effect]
  • glucose intolerance/si [Side Effect]
  • headache/si [Side Effect]
  • human
  • human t cell leukemia virus 1
  • hyperlipidemia/si [Side Effect]
  • hypertension/si [Side Effect]
  • inhalational drug administration
  • insomnia/si [Side Effect]
  • intramuscular drug administration
  • intrathecal drug administration
  • intravenous drug administration
  • leukopenia/si [Side Effect]
  • liver failure/si [Side Effect]
  • major clinical study
  • male
  • methylprednisolone/ae [Adverse Drug Reaction]
  • methylprednisolone/ct [Clinical Trial]
  • methylprednisolone/do [Drug Dose]
  • methylprednisolone/dt [Drug Therapy]
  • mizoribine/ae [Adverse Drug Reaction]
  • mizoribine/ct [Clinical Trial]
  • mizoribine/dt [Drug Therapy]
  • moon face/si [Side Effect]
  • motor dysfunction/dt [Drug Therapy]
  • motor dysfunction/th [Therapy]
  • muscle weakness/si [Side Effect]
  • nausea/si [Side Effect]
  • obesity/si [Side Effect]
  • oral drug administration
  • osteoporosis/si [Side Effect]
  • pentoxifylline/ae [Adverse Drug Reaction]
  • pentoxifylline/ct [Clinical Trial]
  • pentoxifylline/dt [Drug Therapy]
  • peptic ulcer/si [Side Effect]
  • plasmapheresis
  • preschool child
  • priority journal
  • protirelin/ct [Clinical Trial]
  • protirelin/dt [Drug Therapy]
  • rash/si [Side Effect]
  • salazosulfapyridine/ae [Adverse Drug Reaction]
  • salazosulfapyridine/ct [Clinical Trial]
  • salazosulfapyridine/dt [Drug Therapy]
  • school child
  • urinary tract infection/si [Side Effect]
  • vertigo/si [Side Effect]
  • vomiting/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Nakagawa M.

  • Nakahara K.

  • Maruyama Y.

  • Kawabata M.

  • Higuchi I.

  • Kubota H.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free